×

Intra-Cellular plunges after schizophrenia drug trial

5:18 PM ET Wed, 28 Sept 2016

Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports.